This report is part of a 12-month Clinical Context series.
|
By Richard Robinson, Contributing Writer, MedPage Today
Published: October 16, 2010
Reviewed by Michael J. Olek, DO; Director, Newport Doctors Multiple Sclerosis Clinic. |
GOTHENBURG, Sweden — Adjunctive simvastatin provided no benefit in multiple sclerosis patients taking intramuscular interferon beta-1a (Avonex), results of a new study showed.
“The study gave a clear result that simvastatin cannot be recommended as an add-on therapy for intramuscular interferon beta-1A,” according to Per Soelberg Sorensen, MD, of Copenhagen University Hospital in Denmark.
But while simvastatin offered no additional disease control compared with placebo, it was safe, Soelberg Sorensen said at the European Committee for Treatment and Research in Multiple Sclerosis meeting.
“We know that statins have immunomodulatory properties” he said, and in a small open trial, simvastatin reduced gadolinium-enhancing lesions in MS.
However, a small trial of atorvastatin as combination therapy in MS indicated it might reduce the effect of subcutaneous interferon beta-1a.
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews